We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
November was a historic month for stocks-- the Dow was up about 11.8% for the month, the S&P 500 rose 10.8% while the Nasdaq gained 11.8%. Unlike earlier this year, when the rally was led mainly by mega-cap tech stocks, economically sensitive areas emerged as the biggest winners last month. The small-cap Russell 2000 index surged about 18.3% -- its best monthly gain ever.
The widening of rally was thanks mainly to very encouraging vaccine trial results from Pfizer (PFE - Free Report) , Moderna (MRNA - Free Report) and AstraZeneca (AZN - Free Report) . Hopes that the presidential transition would be smooth have also boosted investor sentiment. Additionally, nomination of Janet Yellen for Treasury secretary has reignited hopes of a large stimulus next year, which would benefit smaller companies a lot.
To learn more the iShares Russell 2000 ETF (IWM - Free Report) , the iShares Core S&P Small-Cap ETF (IJR - Free Report) and the Vanguard Small Cap Growth ETF (VBK - Free Report) that soared in November, please watch the short video above.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Small Cap ETFs Deliver Big Gains for Investors
November was a historic month for stocks-- the Dow was up about 11.8% for the month, the S&P 500 rose 10.8% while the Nasdaq gained 11.8%. Unlike earlier this year, when the rally was led mainly by mega-cap tech stocks, economically sensitive areas emerged as the biggest winners last month. The small-cap Russell 2000 index surged about 18.3% -- its best monthly gain ever.
The widening of rally was thanks mainly to very encouraging vaccine trial results from Pfizer (PFE - Free Report) , Moderna (MRNA - Free Report) and AstraZeneca (AZN - Free Report) . Hopes that the presidential transition would be smooth have also boosted investor sentiment. Additionally, nomination of Janet Yellen for Treasury secretary has reignited hopes of a large stimulus next year, which would benefit smaller companies a lot.
To learn more the iShares Russell 2000 ETF (IWM - Free Report) , the iShares Core S&P Small-Cap ETF (IJR - Free Report) and the Vanguard Small Cap Growth ETF (VBK - Free Report) that soared in November, please watch the short video above.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>